Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Pharm Assoc (Wash). 1998 May-Jun;38(3):354-61; quiz 362-3.

The role of pharmacy in the management of patients with temporomandibular disorders and orofacial pain.

Author information

  • 1Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville 32610-0494, USA. brazeau@cop.health.ufl.edu

Abstract

OBJECTIVE:

To provide information regarding the current understanding of the etiology and treatment, both nonpharmacologic and pharmacologic, of orofacial pain conditions including temporomandibular disorders (TMDs). This review briefly discusses the etiology and pathophysiology underlying the development of TMDs, generally accepted nonpharmacologic methods of treatment, and the most common current pharmacologic management approaches.

DATA SOURCES:

Current medical literature and the authors' clinical experiences.

DATA SYNTHESIS:

TMDs encompass a number of diagnostic subgroups that involve the masticatory musculature, the temporomandibular joint(s), and associated structures. More than 10 million individuals in the United States are affected by TMDs. Most current pharmacologic management approaches in the treatment of orofacial pain conditions, including TMDs, involve the use of antidepressants, anticonvulsants, muscle relaxants, corticosteroids, and nonsteroidal anti-inflammatory drugs.

CONCLUSION:

Inclusion of pharmacists who are knowledgeable in the nonpharmacologic and pharmacologic treatment approaches on the TMD management team would improve therapeutic monitoring, follow-up, and outcomes in these patients.

PMID:
9654866
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk